The French Senate has formally submitted an opinion to the Council of the European Union on the proposed European Biotech Act, assessing its compliance with the Principles of Subsidiarity and Proportionality. The opinion, dated 6 July 2026 and transmitted as a cover note (11879/26), concerns the Proposal for a Regulation establishing a framework to strengthen the Union's biotechnology and biomanufacturing sectors, particularly in health, and amending six named Regulations (COM (2025) 1022 final).
The opinion was sent by the French Senate to the President of the Council, with the Council receiving it on 6 July 2026. The document is available in French and an English translation, with translations possibly accessible on the IPEX website. This marks the first recorded subsidiarity scrutiny from a national parliament on this file, as no prior coverage of the European Biotech Act exists in recent months.
The European Biotech Act, proposed by the European Commission, aims to boost the EU's biotechnology and biomanufacturing sectors, with a focus on health applications. It includes amendments to existing regulations on novel foods, advanced therapy medicinal products, clinical trials, veterinary medicinal products, and the Strategic Technologies for Europe Platform (STEP) and Critical Medicines Act. The French Senate's opinion will be considered by the Council as part of the legislative process, potentially influencing the final text.
The opinion could affect the pace of legislative progress, as national parliament scrutiny may lead to adjustments in the proposal. For EU biotech firms, the Act promises streamlined regulatory pathways and increased investment, but any changes driven by subsidiarity concerns could alter the scope of EU-level intervention. National health authorities may see their roles clarified or constrained depending on the final balance of EU and member state competences. Patient groups stand to benefit from faster access to innovative therapies, though delays in adoption could postpone these benefits.
The Council will review the French Senate's opinion alongside other national parliament submissions. The European Parliament is expected to begin its examination of the proposal in the coming months, with the Committee on the Environment, Public Health and Food Safety (ENVI) likely leading the file.